Business Wire

Adtran launches Mosaic One Clarity to transform network operations with AI-based predictive maintenance and proactive assurance

14.10.2025 14:00:00 CEST | Business Wire | Press release

Share

News summary: Service providers face mounting operational strain from costly site visits and complex troubleshooting Adtran’s Mosaic One Clarity, built on its REAL AI platform, delivers explainable insights, guided actions and continuous learning Operators can resolve issues faster and deliver proactive support, boosting efficiency and customer experience

Adtran today launched Mosaic One Clarity – a new artificial intelligence solution designed to help service providers simplify network operations and improve efficiency. Built on Adtran’s REAL AI platform, the new Mosaic One module is already in several customer trials. It uses advanced reasoning and explainable intelligence to deliver predictive maintenance, actionable insights and guided steps that help teams resolve issues quickly and confidently across multi-vendor network environments. By consolidating network and subscriber data, Mosaic One Clarity enables faster root cause analysis, reduces site visits and shortens repair times. Unlike one-size-fits-all approaches, REAL AI applies the right techniques where they deliver measurable value. It gives operators immediate benefits, boosting service quality and enhancing customer experience without major infrastructure changes.

“Mosaic One Clarity is about helping service providers simplify operations and gain greater control over their networks,” said Christoph Glingener, CTO of Adtran. “Built on our REAL AI engine, this new solution puts AI intelligence directly into the workflow so CSRs, NOC engineers and field crews can make the right call in minutes. And because it’s part of our Mosaic One suite, service providers can see operational gains on day one without major changes to their network. Teams start with guided steps and progress to prevention and automation at their own pace. The impact is fewer avoidable visits, faster restoration and better service status for subscribers.”

Mosaic One Clarity is built on Adtran’s REAL AI platform, which combines the principles of Reasoning, Explaining, Acting and Learning to deliver practical intelligence for network operations. REAL AI applies deterministic reasoning to identify likely causes of service disruptions and performance issues at scale across multi-vendor access and in-home networks. Explainable insights give teams precise understanding of what’s happening and why, so they can act with confidence, while guided steps and governed controls enable actions such as proposing remedies, rebooting gateways on approval, updating tickets and notifying subscribers. A continuous learning loop strengthens reasoning by detecting patterns over time. Built as a secure, open, carrier-grade platform, REAL AI supports integration with existing workflows and future AI agents, helping operators adopt advanced capabilities in phases without expensive system overhauls.

“We’re excited to be among the first service providers trialing Adtran’s Mosaic One Clarity solution,” commented Sean M. McGrath, GM and CEO of ACE Fiber. “Recently, we’ve been expanding our fiber network at pace, and that’s introduced new complexity and increased pressure on our teams. Adtran’s new AI solution gives us the visibility and control to stay ahead. It enables us to detect early warning signs, understand subscriber impact and take decisive action before services are disrupted. That means fewer field dispatches, more first‑time resolutions and a better experience for the communities we serve every day. Early results speak for themselves. We’re projecting up to 75% fewer trouble tickets every month. That means it’s already easing operational strain, improving team productivity and raising customer satisfaction.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by 
ADTRAN Holdings, Inc. 
www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014228660/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye